Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis

NCT07933133 is registered in ClinicalTrials.gov with CSPC-NBP Pharmaceutical Co., Ltd. as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07933133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis
Lead sponsor
CSPC-NBP Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
February 1, 2030
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 7 arms.

  • Group A1 ExperimentalSYH9061

    Group SYH9061 4 mg

  • Group A2 Placebo comparatorPlacebo

    Group Placebo

  • Group B1 ExperimentalSYH9061

    Group SYH9061 6 mg

  • Group B2 Placebo comparatorPlacebo

    Group Placebo

  • Group C1 ExperimentalSYH9061

    Group SYH9061 4 mg

+2 more arms

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change in FVC from baseline (mL) Week 12

    FVC is one of the pulmonary function indicators; FVC values in patients with IPF tend to decrease.

Lead sponsor's other trials

CSPC-NBP Pharmaceutical Co., Ltd., most recent start first.

Similar trials

Same condition (Idiopathic Pulmonary Fibrosis) and phase, most recent start first.